Jack Cush

The first day of EULAR 2026 in London featured the opening ceremonies, a plenary session, posters nd the first round of major oral presentations to an audience of nearly 15,000 attendees.. Here are a few of my favorites from the first day.

Day two at EULAR 2026 was jammed with sessions on advances in immune checkpoint inhhbitors (and irAEs), Lupus, Scleroderma, RA and IgG4 related disease. Here are a few of my favorites from Day 2.

The last day in London was exciting as both the Late-Breaking abstracts and new EULAR guidelines were presented. Guidelines presented addressed several significant unmet need areas including PMR, GCA, Takayasu's arteritis, Vaccinations in Rheumatic patients, Imaging in spondyloarthritis and classification criteria for the Anti-Synthetase Syndrome. Here are but a few of my favorites from a list of many quality sessions.

Its time for Rheumatology RoundUp from EULAR 2026 from London, UK. Drs. Artie Kavanaugh and jack Cush review their choice presentations from the meeting, offering their perspectives on impact and applicability.

The RA-BRIDGE and RA-BRANCH studies were presented as a late-breaking abstract at EULAR 2026 ( LB0009 ). This was the pooled results from two large FDA post-marketing commitment safety trials — RA-BRIDGE (global) and RA-BRANCH (US-only) — comparing baricitinib (BARI) at 2 mg and 4 mg daily against TNF inhibitors (etanercept or adalimumab) in RA patients specifically enriched for venous thromboembolic event (VTE) risk factors.

Jun 22, 2026 10:00 am Know-it-now Axial spondyloarthritis must be actively excluded, especially in males under age 40 years.

An editorial in Lancet Rheumatology , calls for "..reframing axSpA as a systemic, autoimmune inflammatory disease with multiorgan involvement and substantial unmet need."

Jun 23, 2026 3:03 pm Know-it-now Anti-CCP remains the diagnostic gold standard, but serologies in combination may become an advantage.

PLoS Medicine has published a population-based retrospective cohort study from the Southern Israeli Pregnancy Registry (siPREG) project showing that 1st trimester exposure to NSAIDs was not associated with major congenital malformatoin (MCM) risk.

JAMA Network Open has publshed that a simple Can a 2-gene blood test may be an objective adjunct to clinical criteria in the diagnosis of early Kawasaki disease in children with febrile illnesses.